Please login to the form below

Not currently logged in
Email:
Password:

Karyopharm

This page shows the latest Karyopharm news and features for those working in and with pharma, biotech and healthcare.

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen has agreed a deal to license a brain disease candidate from Karyopharm for $10m upfront, and up to $217m in milestone payments.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Option, licence. 223. Karyopharm Therapeutics/ Biogen. Oral SINE compound KPT-350 (IND ready) other assets for neurological and neurodegenerative conditions.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...